RxDoctor Payments Data

Cecil Robertson, MD

Hematology & Oncology · Titusville, FLNPI 1780640631

Payments from drug & device makers

$2,055in general payments, 2019–2025

Across 88 payments — averaging $23.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$370
  • Novartis$245
  • Novocure Inc.$175
  • AstraZeneca$147
  • E.r. Squibb & Sons, L.L.C.$136
  • Sanofi$90
  • plus $892 from 26 others

What the payments were for

  • Food & beverage$2,055100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,055 in reported general payments places this provider in the 25th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$37,447
Medicare patients
266
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib13$208,847
Lenalidomide16$194,718
Abiraterone Acetate45$159,237
XtandiEnzalutamide16$153,931
EliquisApixaban61$44,748
Imatinib Mesylate21$11,587
Bicalutamide41$1,067
Ondansetron OdtOndansetron47$957
Prochlorperazine Maleate69$887
Anastrozole39$702
Prednisone101$647
Tamoxifen Citrate27$599
Dexamethasone31$552
Hydroxyurea24$551
Letrozole36$396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$56$253,59574 claims
Astellas Pharma US IncXtandi$65$153,93116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Titusville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →